Wire · opportunities
Roivant to Present Phase 2 Mosliciguat Data for PH-ILD on Tuesday
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 September 2026 · Fusion42 review
Roivant and Pulmovant will present Phase 2 data for mosliciguat in pulmonary hypertension associated with interstitial lung disease, focusing on how the drug affects pulmonary vascular resistance over 24 weeks. The data will determine if mosliciguat, which activates a different enzyme form than current treatments, merits advancement to Phase 3 trials.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You need to prepare for a shift in pulmonary hypertension treatment as mosliciguat could define new efficacy benchmarks and open a path where existing drugs falter. This data readout lets you decide fast on drug development bets tied to this niche lung disease.
◆ Coverage
1 source · 6 Sep 2026
◆ Related on Wire
◆ Topics